Kinzalkomb (telmisartan;hydrochlorothiazide)
- Region
- 🇪🇺 EU
- Active substance
- telmisartan;hydrochlorothiazide
- Company
- Bayer AG
- Status
- Withdrawn
- Therapeutic area
- Hypertension
- EU approval
- Fri 19 Apr 2002
- Application
- EMEA/H/C/000415
- ATC
- C09DA07
- Official record
- www.ema.europa.eu
Indication
Treatment of essential hypertension. Kinzalkomb fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide, 80 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on telmisartan alone. Kinzalkomb fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on Kinzalkomb (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 PritorPlus Withdrawn · Bayer AG
- 🇪🇺 Tolucombi Authorised · KRKA tovarna zdravil d.d. Novo mesto
- 🇪🇺 MicardisPlus Authorised · Boehringer Ingelheim International GmbH
- 🇪🇺 Actelsar HCT Authorised · Actavis Group PTC ehf
Follow Kinzalkomb
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.